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Melatonin has been known to be a chemopreventive agent since 
its levels inversely correlate with the risk of developing cancer. We 
have recently shown that melatonin induces p38-dependent phos-
phorylation of both p53 and histone H2AX. This is associated with 
a p53-mediated increase in repair of both endogenous and chemo-
therapy-induced DNA damage. In addition, the inhibition of p38 
activities impairs melatonin’s capability to induce a p53-depend-
ent DNA damage response and thus its ability to maintain genome 
integrity. Since melatonin-induced p53 phosphorylation requires 
an intact p38 phosphorylation cascade and p38 can be activated 
by G proteins, we supposed that melatonin’s activities could be 
mediated by its G-protein-coupled membrane receptors, MT1 
and MT2. Here, we show that the activation of the p53-dependent 
DNA damage response by melatonin is indeed mediated by MT1 
and MT2. As a result, the absence of either receptor impairs mel-
atonin’s ability to reduce both cell proliferation and clonogenic 
potential of cancer cells. In addition, this causes an impairment of 
the p53-dependent DNA damage response. By providing molecu-
lar insight, our findings might have translational impact, suggest-
ing the involvement of melatonin receptors in tumorigenesis.
Introduction
Melatonin (N-acetyl-5-methoxytryptamine) is a mammal pineal hor-
mone mainly secreted by the pineal gland at the hypothalamic level. 
Melatonin synthesis occurs mainly at night and is tuned by enzymes 
inhibited by the sunlight (1). Increasing observational evidence associ-
ates melatonin concentration to cancer occurrence (2–9). In particular, 
two epidemiological studies have demonstrated an inverse correlation 
between overnight urinary levels of melatonin and the incidence of 
breast cancer (8,9). The first study was conducted within the ORDET 
cohort and tested the concentration of a melatonin metabolite, 6-sulfa-
toxymelatonin, in 178 postmenopausal women with incident breast 
cancer and 710 matched controls (8), whereas the second one refers 
to a case–control study conducted within the NHIS cohort on 357 
postmenopausal women with incident breast cancer and 533 matched 
controls (9). These and other similar studies suggest that melatonin 
might be able to induce tumour suppressor pathways in vivo (10,11). 
Molecular studies have shown that melatonin is able to induce both 
the p53 tumour suppressor and its target gene p21 (10,12–14). In 
response to a plethora of stressful conditions, especially those caus-
ing DNA damage, p53 undergoes post-translational modifications, 
becomes more stable and its transcriptional activities are enhanced 
(15–23). Particularly, upon DNA damage, p53 is phosphorylated by 
a subset of kinases. Ataxia telangiectasia mutant and ataxia telangi-
ectasia related phosphorylate p53 upon DNA double strand breaks, 
whereas p38 can phosphorylate p53 in response to single strand 
breaks or in the absence of ataxia telangiectasia mutant (15,22,23). In 
addition, in the presence of radical oxygen species, both p53 and p38 
become phosphorylated (24–29).
We have recently published that melatonin triggers a p38- and 
PML-dependent phosphorylation cascade, resulting in p53 phospho-
rylation in Ser-15 (14).
Having a high lipid-water solubility, melatonin is able to enter the 
cell by diffusing across the cellular membrane and act as a radical 
scavenger. In the same way, it can cross the nuclear membrane and 
bind its nuclear receptor RZR/RORα. This is then recruited onto RZR 
regulatory elements present in the promoters of several genes, such as 
p21 and 5-lipoxygenase, which are thereby transcriptionally regulated 
(10). In addition, melatonin regulates signalling pathways by binding 
to its membrane receptors, MTNR1A and MTNR1B, also known as 
MT1 and MT2, which exist in the homodimeric and heterodimeric 
states (30–33). Both MT1 and MT2 are G-protein-coupled membrane 
receptors which, upon ligand binding, activate G proteins and inhibit 
cyclic adenosine 3′,5′-monophosphate formation (10,34). It has been 
shown that both MT1 and MT2 receptors, upon melatonin binding, 
can also activate MAP kinases, among which c-Jun, in Chlorocebus 
aethiops Cos-7 cells (30). Since we found that melatonin treatment 
leads to p38 accumulation (14), we investigated whether this was 
receptor mediated. In the present manuscript, we show that melatonin 
triggers p53 phosphorylation through the activation of its receptors, 
MT1 and MT2. In fact, we show that both chemical inhibition and 
selective gene silencing of the receptors impair melatonin’s ability 
to trigger p38 phosphorylation and accumulation, thereby inhibiting 
p53 phosphorylation. This pairs with a decrease in melatonin’s abil-
ity to reduce cell proliferation and prevent DNA damage. Together 
with recent translational studies showing reduced levels of melatonin 
receptors in cancer samples as compared with their matched controls 
(35,36), these findings suggest that the involvement of melatonin 
receptors in triggering anticancer pathways.
Materials and methods
Cell culture and transfection
HCT116 and MCF-7 cells were cultured in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal calf serum, 2 mM l-glutamine, 100 U/
ml penicillin and 100 µg/ml streptomycin (Gibco, Life Technologies, Carlsbad, 
CA). Cell lines were grown at 37°C, 5% CO2. Transfections were performed 
with Lipofectamine 2000 (Life Technologies) according to the manufacturer’s 
recommendations, using the following small interfering RNA (siRNA): siGFP 
5′-AAGUUCAGCGUGUCCGGGGAG(dTdT)-3′; siMTNR1A 5′-GGAAUA
CAGGAGAAUUAUA(dTdT)-3′; siMTNR1B 5′-CUAGCUACUUACUGGC
UUA(dTdT)-3′ (Eurofins MWG, Ebersberg, Germany). Culture medium was 
replaced 24 h post-transfection and cells were allowed to grow for additional 
72 h before any treatment.
Reagents
Melatonin (M5250) and Luzindole (L2407) were purchased from Sigma–
Aldrich (St Louis, MO).
Growth curves and colony-forming assays
For growth curves, 7 × 103 cells/well were seeded in 6-well dishes. Cells 
were harvested at the indicated times by trypsin detachment and counted 
automatically using a Guava EasyCyte 8HT flow cytometer (Millipore, 
Billerica, MA). Cell concentration (cells/ml) is shown on the y-axis. With 
regard to colony-forming assays, 5 × 102 cells were seeded in 35-mm dishes 
and grown for 15 days. Cells were stained with crystal violet and colonies were 
counted. To maintain melatonin levels, the medium was changed every 48 h in 
both experiments.
Western blots
Total protein extracts were prepared by lysing cells in 8 M urea (Bio-
Rad, Hercules, CA). Receptors were extracted with 8 M urea/10 mM 
[(3-cholamidopropyl)-dimethyl-ammonio]1-propanesulfonate (Bio-Rad). All Abbreviation: siRNA, small interfering RNA.
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protein extracts were quantified by Bradford assay and equal amounts were 
loaded onto sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
(either pre-cast 4–20% Novex Tris-Glycine gels from Life Technologies 
or home-made gels), transferred to polyvinylidene fluoride membranes 
(Immobilon-P, Millipore) and underwent immunoblot with the indicated anti-
bodies. Antibodies to phospho-p53 Ser-15 (9284, Cell Signaling, Danvers, 
MA), β-actin (A2288, AC-74, Sigma), p21 (2947, Cell Signaling), nucleo-
lin (ab13541, 4E2, Abcam, Cambridge, UK), MTNR1A (ab87639, Abcam), 
MTNR1B (ab128469, Abcam), γH2AX (9718, 20E3, Cell Signaling), p38 
(9212, Cell Signaling), phospho-p38 Thr180/Tyr182 (9211, Cell Signaling) 
and p53 (sc126, DO1, Santa Cruz Biotechnology) were diluted in 5% bovine 
serum albumin in Tris-buffered saline/0.1% Tween-20. Secondary anti-
mouse and anti-rabbit antibodies were purchased from Bio-Rad. Images were 
acquired using a VersaDoc MP instrument (Bio-Rad).
Comet assays
Following transfection with the indicated siRNA, cells were treated with 
melatonin for 2 h and then irradiated at a dose of 0.05 J/cm2 using a Bio-Sun 
irradiation apparatus (Vilbert Lourmat, Marne-la-Vallée, France) as described 
previously (37) and allowed to repair DNA for 4 h. After treatment, cells were 
detached with trypsin and embedded in 1% low melting agarose (Sigma) in 
phosphate-buffered saline and spread onto microscopy slides coated previously 
with 1% agarose (Bio-Rad). Cells were lysed in the lysis solution (2.5 M NaCl, 
100 mM ethylenediaminetetraacetic acid, 10 mM Tris base, 8 g/l NaOH, 1% 
Triton X-100, 10% dimethyl sulfoxide) for 1 h at room temperature and then 
run in running solution (300 mM NaOH, 1 mM ethylenediaminetetraacetic 
acid, pH 13.0) for 30 min at 25 V and 250 mA. DNA was equilibrated with 
0.4 M Tris (pH 8.0) and slides were dried with methanol. DNA was stained 
with propidium iodide (Sigma) and pictures were taken using ×60 magnifi-
cation on an Axiovert 200M microscope and Axiovision acquisition program 
(Zeiss). At least 300 cells were scored for each slide.
Mice xenografts
Four-week-old CD1 nude mice (n = 7/each group, Charles River) were sub-
cutaneously injected with either HCT116 p53 wt or HCT116 p53−/− cell lines 
(2 × 106 cells/mouse) treated with 1 µM melatonin or vehicle (ethanol) for 72 h, 
changing the medium every 24 h. Tumour volume was evaluated twice a week. 
Animals were killed and xenograft excised after 2 weeks from the injection. 
Tumour volume (mm3) was calculated as follows: 0.5 × D1 × D2, where D1 
and D2 are the larger and smaller diameters measured by caliper. All tumori-
genicity assays were carried out according to the guidelines set by the Internal 
Ethical Committee.
Results
Melatonin reduces DNA fragmentation through its membrane 
receptors
We have shown that melatonin reduces DNA fragmentation following 
treatment with DNA damaging agents, such as chemotherapeutic drugs 
and ionizing radiation (14). In addition, we found that this event is medi-
ated by p38 mitogen-activated protein kinase activating p53 (14). It is 
well known that melatonin can activate signalling pathways by binding 
to its membrane G-protein-coupled receptors MT1 and MT2 with high 
affinity (10,30,32–34). Since MAP kinases, such as c-Jun, are known to 
be activated by G proteins (30), we sought to investigate whether the p53- 
and p38-dependent reduction in DNA fragmentation by melatonin was 
triggered by receptor signalling. To this purpose, we selectively inhibited 
the expression of each melatonin receptor by siRNA in both HCT116 and 
MCF-7 cell lines and treated them with 1 μM melatonin for 2 h to induce 
DNA repair proteins (14). Cells underwent UVB irradiation at a sublethal 
Fig. 1. Induction of DNA repair by melatonin occurs through melatonin membrane receptors. HCT116 (A) and MCF-7 (B) cells were transfected with the 
indicated siRNA. Ninety-six hours post-transfection cells were either treated or not treated with 1 μM melatonin for 2 h. Cells were subjected to irradiation 
with 0.05 J/cm2 UVB and allowed to repair for 4 h. Cells were then subjected to comet assay. Histograms show the percentage of comets normalized to control. 
***P < 0.001; *P < 0.05.
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dose and were allowed to repair damaged DNA. As shown previously 
with chemotherapeutic drugs and gamma-irradiation (14), melatonin 
was able to induce repair of fragmented DNA following UVB irradia-
tion as well, both in HCT116 (Figure 1A) and in MCF-7 (Figure 1B). 
However, in the absence of either MT1 or MT2, the number of cells 
showing DNA fragmentation was not affected by melatonin treatment in 
either of the cell lines (Figure 1A and B). In addition, comet assays were 
performed in both HCT116 (Supplementary Figure S1A, available at 
Carcinogenesis Online) and MCF-7 (Supplementary Figure S1B, avail-
able at Carcinogenesis Online) by either pre-treating or not pre-treating 
the cells with 1 nM luzindole, a melatonin antagonist binding to and inac-
tivating both MT1 and MT2 receptors, which is known to inhibit both 
receptors, though it has a 25-fold higher affinity for MT2 (38). Luzindole 
impaired melatonin’s ability to reduce DNA fragmentation following 
UVB irradiation (HCT116 cells in Supplementary Figure S1A, avail-
able at Carcinogenesis Online and MCF-7 cells in Supplementary Figure 
S1B, available at Carcinogenesis Online). Both the approaches indicated 
that receptor function is necessary for melatonin’s ability to induce repair 
of fragmented DNA following UVB irradiation.
Receptor-mediated reduction of DNA damage is p53 dependent
We have shown previously that melatonin’s ability to reduce DNA 
fragmentation was impaired in cells lacking p53 (14). In order to 
understand whether receptor-mediated DNA repair induced by 
melatonin was triggered mainly by p53, we performed comet assays 
(as described for Figure 1) in syngenic HCT116 cells, either wild-type 
(wt) or null for p53. As for other types of DNA damage (14), melatonin 
was not able to induce repair of fragmented DNA caused by UVB 
irradiation in the absence of p53 (Figure  2B). Moreover, although 
removal of either MT1 or MT2 by siRNA impaired melatonin’s abil-
ity to reduce DNA fragmentation in HCT116 wild-type cells, it did 
not have any further effect in HCT116 p53 null cells (Figure 2A and 
B) demonstrating that removal of either receptor impairs the activa-
tion of p53 by melatonin. Of note, HCT116 p53 null cells have been 
reported to express two p53 isoforms (39–41). Thus, our results are 
consistent with the need of full-length p53 for DNA repair.
Blockage of melatonin receptors impairs melatonin’s ability to 
reduce cell proliferation
Melatonin has proven to be able to inhibit proliferation of cancer cells 
(12–14). Here, we investigated whether activation of receptors was 
involved in this process. In order to do this, we silenced MT1 or MT2 
expression in MCF-7 (Figure  3A), HCT116 p53 wt (Figure  3B) and 
HCT116 p53 null (Figure 3C) cells. Colony-forming assays showed that 
depletion of either receptors by siRNA impaired melatonin’s ability to 
inhibit long-term proliferation (Figure 3A and B). The same effects were 
observed in short-term proliferation, as assessed by growth curves in 
both HCT116 (Figure 3D) and MCF-7 (Figure 3E). In the absence of 
Fig. 2. Melatonin membrane receptors trigger p53-dependent DNA repair. HCT116 wt (A) and HCT116 p53−/− (B) cells were transfected with the indicated 
siRNA and either treated or not with 1 μM melatonin for 2 h. Cells were subjected to irradiation with 0.05 J/cm2 UVB and allowed to repair for 4 h. Cells were 
then subjected to comet assay. Histograms show the percentage of comets normalized to control. ***P < 0.001.
1053
R.Santoro et al.
Fig. 3. Melatonin inhibition of cell proliferation is receptor mediated. MCF7 (A), HCT116 wt (B) and HCT116 p53−/− (C) cells were transfected as in Figure 1, 
seeded and allowed to form colonies for 15 days. Culture medium (without or with 1 μM melatonin) was replaced every second day to keep melatonin levels 
constant. Colonies were stained and counted. Histograms show the percentage of cells relative to untreated cells. ***P < 0.001; **P < 0.01. HCT116 (D) and 
MCF-7 (E) cells were seeded and allowed to grow for the indicated time. Culture medium (without or with 1 μM melatonin) was replaced every second day to 
keep melatonin levels constant. Cell number was counted with the Guava EasyCyte 8HT flow cytometer. Cell concentration is shown in the graphs.
1054
Melatonin receptors trigger p53-dependent DNA repair
p53, removal of melatonin receptors did not have any effect on cell pro-
liferation (Figure 3C). Besides the genetical approach, we chemically 
inhibited both MT1 and MT2 functions by using luzindole. Melatonin 
inhibited long-term cell growth only in the presence of p53 and in the 
absence of luzindole both in HCT116 (Supplementary Figure S2A and 
B, available at Carcinogenesis Online) and in MCF-7 (Supplementary 
Figure S2C and D, available at Carcinogenesis Online) cells. These 
experiments showed that intact receptor function mediated the reduction 
in cell proliferation by melatonin.
To explore the antitumorigenic potential of melatonin, we subcuta-
neously inoculated immunodeficient CD1 mice with human HCT116 
p53 wt and HCT116 p53 null, which have been either treated or not 
treated with melatonin for 72 h. All mice were killed 21 days after 
the injection. As shown in Figure 4A, melatonin treatment induced 
a specific inhibitory response and robustly interfered with tumour 
growth in HCT116 p53 wt, as shown by the distribution of tumour 
volumes among the four groups of HCT116 p53 wt and HCT116 
p53−/− injected mice at the time of the last measurement (Figure 4A). 
This difference was due to a melatonin-induced reduction of prolif-
eration in p53-expressing cells, as demonstrated by the decrease of 
Ki-67 protein expression in the HCT116 p53 wt xenografts, which 
was not observed in HCT116 p53−/− xenografts (Figure 4B).
Melatonin membrane receptors trigger p53 activation
Melatonin has been shown to induce a p38-dependent p53 phosphorylation 
in Ser-15 (14). However, little is known about the mechanisms 
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underlying the activation of p38 and p53 by melatonin. We deduced 
that, since melatonin’s chemopreventive activities such as reduction of 
cell proliferation and DNA fragmentation were receptor mediated, p53 
activation by melatonin could occur through receptor activation as well. 
In order to ascertain whether melatonin receptors were involved in p38 
activation and p53 phosphorylation, we performed immunoblots in both 
HCT116 and MCF-7 cells depleted for either MT1 or MT2 by siRNA. 
As shown in Figure 5A and B and Supplementary Figure S3A and B, 
available at Carcinogenesis Online, melatonin induced an increase in 
p38 protein levels as well as phosphorylation of both p38 in Thr180/
Tyr1182 and p53 in Ser-15. Depletion of either MT1 or MT2 impaired 
melatonin’s ability to induce p38 and p53 phosphorylation. This 
indicated that these events are caused by a signal transduction mediated 
by the binding of melatonin to its receptors. We performed the same 
kind of experiment following chemical inhibition of melatonin receptors 
MT1 and MT2 with luzindole. Inhibition of melatonin receptors by 
this approach impaired the signal transduction pathway triggering p53 
phosphorylation (Figure 5C and D and Supplementary Figure S3C and 
D, available at Carcinogenesis Online). In addition, we knocked down 
simultaneously MT1 and MT2 receptors in both the cell lines. Similar 
to luzindole treatment, lack of the receptors impaired melatonin-induced 
signal transduction (Figure 5E and F and Supplementary Figure S3E and 
F, available at Carcinogenesis Online).
p38 and p53 are phosphorylated following DNA damage and 
radical oxygen species generation (24–29). In order to investigate 
whether melatonin receptors could trigger p38 activation in response 
to DNA damage, we tested the impact of simultaneous knock-
down of MT1 and MT2 on p38 phosphorylation following UVB 
irradiation. UVB irradiation induced a massive phosphorylation of 
p38, which was completely impaired in the absence of melatonin 
receptors (Figure  5G and Supplementary Figure S3G, available at 
Carcinogenesis Online). This further strengthened our observation 
that melatonin receptor signalling triggers a p38- and p53-dependent 
DNA damage response.
It is worth noting that silencing of either receptor induced an increase 
in p38 and p53 levels (Figure  5A and B, E and F), possibly due to 
generation of DNA fragmentation (data not shown). Treatment of cells 
with melatonin following silencing of MT1 induced a decrease in both 
p38 and p53 phosphorylation, whereas this did not happen when MT2 
was knocked down (Figure 5A and B and Supplementary Figure S3A 
and B, available at Carcinogenesis Online). It has been reported that 
melatonin receptors have a different ability to trigger phosphorylation 
upon melatonin binding (31), with MT1 being more effective than MT2. 
In addition to inducing a receptor-mediated phosphorylation cascade, 
melatonin acts as a radical scavenger within the cells, thereby reducing 
the phosphorylation of p38 and p53. We believe that, in the absence of 
MT1, MT2 activation by melatonin cannot cope with melatonin poten-
tial as a radical scavenger and this results in reduction of radical oxygen 
species-induced phosphorylation of p53 and p38.
Discussion
Epidemiological studies have clearly demonstrated that high levels 
of melatonin decrease the risk of developing various types of cancer, 
among which breast and colon cancer (2–9). Only recently some 
light has been shed on the mechanisms underlying melatonin’s 
chemopreventive actions (10,12–14). In particular, melatonin has 
been shown to regulate the expression of both p53 and p21 (13) and 
to increase p38-mediated p53 phosphorylation in cancer cells (12,14). 
In experimental studies, the induction of the p38 and p53 pathways 
has different outcomes according to the dose of melatonin used. When 
cells are treated with doses of melatonin close to either physiological 
levels or levels reached during the treatment of sleep disorders (1 nM 
to 0.5 μM), p53 is activated through phosphorylation in Ser-15 and 
cells undergo a transient cell cycle arrest, during which they can repair 
damaged DNA (14). Conversely, when cells are treated with higher 
doses of melatonin (0.5–2 mM), p53 phosphorylation as well as total 
p53 levels are markedly increased and apoptosis is induced (12). 
This is not surprising since, in response to stressful conditions, the 
transcription factor p53 undergoes post-translational modifications, 
such as acetylation, phosphorylation and sumoylation (15–23,42,43). 
Once modified, p53 binds the DNA and activates the transcription 
Fig. 4. Melatonin reduces the growth of cancer cells in xenograft models. HCT116 wt (A) and HCT116 p53−/− (B) cells were treated with 1 μM melatonin or 
vehicle for 72 h and subcutaneously injected into CD1 mice. Dot plots show tumour volume (left panel) and proliferation index (right panel) as assessed by Ki-67 
immunostaining, for which sample images are shown. P-values are indicated on the graphs.
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of a plethora of target genes, which can cause a variety of cellular 
responses, ranging from cell cycle arrest to apoptosis (17,19,43,44). 
In particular, when cells undergo sublethal DNA damage, p53 is 
phosphorylated by DNA damage activated kinases, such as ataxia 
telangiectasia mutant, ataxia telangiectasia related and p38 mitogen-
activated protein kinase, and activates genes inducing cell cycle arrest, 
such as p21 (15,17,21–23). When this occurs, a DNA repair response is 
induced, in which phosphorylated p53 plays a central role (19,21,44). 
We have demonstrated previously that melatonin is able to induce 
a p38-dependent phosphorylation cascade, which determines the 
phosphorylation of both p53 in Ser-15 and histone H2AX in Ser-139 
(14). Here, we show that melatonin triggers a p38- and p53-mediated 
DNA damage response through activating receptors (Figures 1 and 
2). In fact, by both selective silencing of melatonin receptors MT1 
and MT2 and their chemical inhibition with melatonin’s antagonist 
luzindole, melatonin’s ability to reduce DNA fragmentation in 
response to ionizing radiation was impaired. Along the same line, 
both removal and inactivation of melatonin receptors weakened 
Fig. 5. Blockage of melatonin membrane receptors impairs melatonin-induced activation of p53. HCT116 (A) and MCF-7 (B) cells were transfected with the 
indicated siRNA. Ninety-six hours post-transfection cells were treated with 1 μM melatonin for the indicated time. Cell extracts were subjected to immunoblot 
with the indicated antibodies. HCT116 (C) and MCF-7 (D) cells were treated with 1 nM luzindole for 15 min, then with melatonin for the indicated time. Cell 
extracts were subjected to immunoblot with the indicated antibodies. HCT116 (E) and MCF-7 (F) cells were transfected with the indicated siRNA. Ninety-six 
hours post-transfection cells were treated with 1 μM melatonin for the indicated time. Cell extracts were subjected to immunoblot with the indicated antibodies. 
(G) HCT116 cells were transfected with the indicated siRNA. Ninety-six hours post-transfection cells were irradiated with 0.05 J/cm2 UVB. Cell extracts were 
prepared at the indicated time post-irradiation and were subjected to immunoblot with the indicated antibodies. Western blot signal quantification for each panel 
is shown in Supplementary Figure S3, available at Carcinogenesis Online.
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Fig. 6. Expression of melatonin receptors is reduced in colon cancer. Box plots showing reduced MT1 (left) and MT2 (right) expression in tumour versus normal 
samples in six publicly available casuistries from Oncomine. (A) Kaiser casuistry [0. No value (5); 1. Cecum adenocarcinoma (17); 2. Colon adenocarcinoma 
(41); 3. Colon mucinous adenocarcinoma (13); 4. Colon signet ring cell adenocarcinoma (2); 5. Colon small cell carcinoma (2); 6. Rectal adenocarcinoma (8); 
7. Rectal mucinous adenocarcinoma (4); 8. Rectal signet ring cell adenocarcinoma (1); 9. Rectosigmoid adenocarcinoma (10); 10. Rectosigmoid mucinous 
adenocarcinoma (2); Kaiser colon. Genome Biol 2007/07/05, 105 samples, MTNR1A Information: mRNA, 19 574 measured genes. Reporter information: 
Human Genome U133 Plus 2.0 Array]; (B) Skrypczak casuistry [0. No value (24); 1. Colorectal adenocarcinoma (45); 2. Colorectal carcinoma (36); Skrzypczak 
colorectal. PLoS One 2010/10/01, 105 samples, MTNR1A Information: mRNA, 19 574 measured genes. Reporter Information: Human Genome U133 Plus 
2.0 Array]; (C) Hong casuistry [0. No value (12); 1. Colorectal carcinoma (70); Hong colorectal. Clin Exp Metastasis 2010/02/01, 82 samples, MTNR1A 
Information: mRNA, 19 574 measured genes. Reporter Information: Human Genome U133 Plus 2.0 Array]. Numbers between brackets indicate the number of 
samples; (D) Farmer casuistry [1. Apocrine breast carcinoma (6); 2. Basal-like subtype of invasive breast carcinoma (16); 3. Luminal-like subtype of invasive 
breast carcinoma (27); Farmer breast. Oncogene 2005/07/07, 49 samples, MTNR1A Information: mRNA, 12 624 measured genes. Reporter Information: Human 
Genome U133A Array]; (E) Desmedt casuistry [1. Breast carcinoma (8); 2. Invasive ductal and invasive lobular breast carcinoma (11); 3. Invasive lobular breast 
carcinoma (13); 4. Invasive tubular and lobular carcinoma (4); 5. Invasive ductal breast carcinoma (158); 6. Medullary breast carcinoma (2); 7. Mucinous breast 
carcinoma (2); Desmedt breast. Clin Cancer Res 2007/06/01, 198 samples, MTNR1A Information: mRNA, 12 624 measured genes. Reporter Information: 
Human Genome U133A Array]; (F) Ginestier casuistry [1. Invasive ductal breast carcinoma (45); 2. Invasive lobular breast carcinoma (1); 3. Medullary breast 
carcinoma (5); 4. Invasive mixed breast carcinoma (2); 5. Tubular breast carcinoma (1); 6. Invasive breast carcinoma (1); Ginestier breast. Clin Cancer Res 
2006/08/01, 55 samples, MTNR1B Information: mRNA, 19 574 measured genes. Reporter Information: Human Genome U133 Plus 2.0 Array].
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melatonin’s activity towards reduction of cell proliferation (Figure 3). 
Melatonin’s anticancer activities can be attributed to p53 activation 
by p38 (14). Furthermore, intact receptor signalling was necessary for 
melatonin-induced DNA damage response. Hence, we proposed that 
blockage of melatonin receptor signalling by either gene silencing or 
chemical inhibition would result in lack of phosphorylation of p53 
following melatonin treatment. Indeed, our experiments showed that 
melatonin could not induce p53 phosphorylation in Ser-15 in the 
absence of intact receptor signalling, which paired to a lack in the 
increase of p38 protein levels (Figure 5). Moreover, we showed that 
removal of either receptor impaired melatonin’s anticancer activities. 
Based on these results, we could speculate that melatonin triggers its 
chemopreventive activities by binding to and activating MT1/MT2 
heterodimers. This is confirmed by previous studies showing that 
melatonin-activated signal transduction is stronger when melatonin 
binds to MT1/MT2 heterodimers as compared with MT1/MT1 and 
MT2/MT2 homodimers (31). In light of these results, we suggested 
that melatonin receptors could play an important role in tumorigenesis. 
In order to ascertain whether they are actually involved in cancer 
pathogenesis, we interrogated tumour data sets with Oncomine 
(www.oncomine.org). We used three independent casuistries of colon 
cancers and three of breast cancers and analysed the transcript levels 
for MT1 and MT2 in cancer versus normal samples (45–50). The data 
sets were produced with Affymetrix Human Genome U133 Plus 2.0 
Array and the analyses were performed by using Oncomine (www.
oncomine.org). For colon cancers, the first (Kaiser, Figure 6A) and 
the second (Skrzypczak, Figure 6B) casuistries are comprised of 105 
samples each; the third one (Hong, Figure  6C) is composed of 82 
samples. For breast cancers, the first casuistry (Farmer, Figure 6D) 
is comprised of 49 samples, the second (Desmedt, Figure 6E) of 198 
samples and the third one (Ginestier, Figure 6E) of 55 samples. In all 
the casuistries, both MT1 and MT2 mRNA expression levels were 
downregulated in cancer versus normal samples, as shown by box 
plots, regardless of tumour type.
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Moreover, we show that melatonin treatment significantly reduced 
the tumour volume as well as the Ki-67 proliferation index of 
p53-expressing cells in vivo (Figure  4), confirming the key role of 
melatonin in the control of cancer cells proliferation.
It has to be noted that published data evidenced an inverse correlation 
between MT1 expression and tumour development (51–53), whereas oth-
ers found a positive correlation (54–56). Importantly, some authors showed 
an inverse correlation between melatonin serum levels and MT1 expres-
sion (57), shading the possibility that enhanced expression of melatonin 
receptors in cancer could be due to lower levels of circulating melatonin.
Several trials have been conducted with melatonin as an adjuvant 
for chemotherapy in cancer patients (58–60) and systematic reviews 
on these data have been published (60,61). The main aim of these 
studies was to understand whether melatonin could have an active role 
in suppressing tumour growth, whereas little attention was paid to 
the side effects of chemotherapy. A systematic review considered and 
analysed also the information related to the physiological response 
to chemotherapeutic treatments (61). Meta-analysis showed that 
the use of melatonin as an adjuvant for chemotherapy significantly 
improved relapse and survival rate as compared with chemotherapy 
alone. Moreover, melatonin treatment ameliorated chemotherapy side 
effects, such as immune response and thrombocytopenia.
Our data provide in vitro and in vivo evidences that melatonin anti-
cancer activities, including DNA damage response and inhibition of 
cell proliferation, are mediated by the activation of the MT1 and MT2 
receptors and analyses on sample data sets for breast and colon cancer 
show that both MT1 and MT2 mRNA levels are reduced in cancer as 
compared with normal colon samples. This represents important infor-
mation for both the design and the analysis of trials involving mela-
tonin either as an adjuvant for chemotherapy or as a chemopreventive 
agent. In fact, when analysing the effects of melatonin on cell growth 
and relapse-free survival, MT1 and MT2 expression in tumours under 
study might acquire great importance. It is expected that patients with 
tumours expressing low levels of melatonin receptors would not respond 
to melatonin treatment in terms of decreasing tumour progression and 
increasing relapse-free survival. However, the same patients could bene-
fit from melatonin’s ability to reduce bystander effects, increase immune 
response and ameliorate side effects due to chemotherapy administra-
tion (thrombocytopenia, anaemia and asthenia). This is confirmed by the 
fact that meta-analysis showed that 1 year survival rate was significantly 
increased by melatonin co-administration with chemotherapy (61).
As for the prospective chemopreventive studies, it could be of interest 
the analysis of possibly arising tumours in subjects treated with mela-
tonin. In fact, melatonin could demonstrate its effectiveness in prevent-
ing the formation of a wide range of tumours, while tumours arising 
despite the treatment could be due to mutations, hypermethylation or 
deletion of either MT1 or MT2. In light of these implications, our work 
might acquire strong relevance for clinical trials involving melatonin 
both as a chemopreventive agent and as an adjuvant for chemotherapy.
Supplementary material
Supplementary Figures 1–4 can be found at http://carcin.
oxfordjournals.org/
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